Apnimed, Inc. (BOATS:APMD) Financings

Apnimed, Inc.

Financings

RaiseDate
Public offering of common stock
Closed: US$220.8M in the latest tranche · US$16 a share · BofA Securities +3
Dealers: BofA Securities (co-lead), Evercore ISI (co-lead), Cantor (co-lead), LifeSci Capital (co-lead)
Use of proceeds: To support commercial readiness and the potential U.S. launch of Oxnimbi, if approved by the FDA
Sep 8, 2026

Read by 6ix AI from the company's releases